Brief: Sol-Gel Announces Positive Top-Line Phase 3 Trial Results Of Twyneo

SOL-GEL TECHNOLOGIES

30/12/2019 12:42

Dec 30 (Reuters) - Sol Gel Technologies Ltd  SLGL.O :
    * SOL-GEL ANNOUNCES POSITIVE TOP-LINE PHASE 3 TRIAL RESULTS
OF
TWYNEO® FOR THE TREATMENT OF ACNE VULGARIS
    * SOL GEL TECHNOLOGIES LTD - ALL CO-PRIMARY ENDPOINTS
ACHIEVED IN
BOTH PHASE 3 CLINICAL TRIALS
    * SOL GEL TECHNOLOGIES LTD - TWYNEO WAS WELL-TOLERATED AND
MAJORITY OF LOCAL SKIN REACTIONS, WHEN REPORTED, WERE MILD AND
IMPROVED OVER TIME
    * SOL GEL TECHNOLOGIES - THERE WERE NO TREATMENT-RELATED
SERIOUS
ADVERSE EVENTS IN STUDY
    * SOL GEL TECHNOLOGIES - TWYNEO AVAILABLE TO PHYSICIANS &
PATIENTS
IN SECOND HALF OF 2021
    * SOL GEL TECHNOLOGIES - LOOK FORWARD TO SUBMITTING NDA FOR
TWYNEO
IN H2 OF 2020
    * SOL GEL TECHNOLOGIES - 4 UNRELATED SERIOUS ADVERSE EVENTS
WERE
REPORTED ACROSS BOTH PHASE 3 TRIALS

Source text for Eikon:  ID:nGNX5TgQSC 
Further company coverage:  SLGL.O 

 ((Reuters.Briefs@thomsonreuters.com;))